Tomas Navratil, serving as Chief Development Officer for Glaukos Corp (NASDAQ: GKOS), executed a sale of company equity on June 16, 2026. The transaction involved the disposition of 1,537 shares of common stock, generating total proceeds of $200,855. Each share was sold at a price point of $130.68. This executive activity takes place while the stock has demonstrated significant momentum, climbing 28% over the trailing twelve months and trading in close proximity to its 52-week high. Valuation metrics from InvestingPro suggest that GKOS may currently trade at premium levels relative to fair value assessments.
The sale was processed in accordance with a Rule 10b5-1 trading plan that Navratil implemented on March 12, 2026. Post-transaction, Navratil's direct holdings in GKOS common stock stand at 88,833 shares. This figure encompasses 39,791 restricted stock units that remain unvested and undelivered. For comprehensive analysis of executive movements and valuation dynamics, InvestingPro provides detailed Pro Research Reports covering GKOS and over 1,400 additional US equities.
Recent corporate developments highlight strong operational performance. Glaukos reported first-quarter 2026 revenue of approximately $150.6 million, marking a 41% year-over-year expansion. This financial result exceeded BTIG's estimate of $129.5 million and the broader consensus estimate of $137.0 million. Following the earnings release, BTIG upgraded its price target to $141 while maintaining a Buy rating. Needham also raised its price target to $136, citing robust revenue performance and strength within the Glaucoma business segment.
Further analyst adjustments reflect positive sentiment regarding future prospects. Needham subsequently increased its price target to $150, focusing on the outlook for Glaukos' corneal treatment offerings. Stifel reiterated a Buy rating and set a $170 price target, expressing optimism following a regulatory meeting concerning the iDose LCD device. BTIG highlighted the product pipeline, raising its price target to $162 and noting the scaling of the iDose product alongside a strong launch for Epioxa.
Market data indicates GKOS closed at $130.68, reflecting a +3.27 point increase or 2.57% gain. After-hours trading showed minimal movement with a 0.00% change. The stock's performance underscores the intersection of executive activity, corporate earnings, and analyst sentiment within the medical technology sector.